July 22, 2019 – Richmond, British Columbia – Eastwood Bio-Medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce that the Company has agreed to begin a joint cooperation program with Beseto International School (“Beseto”), a school in South Korea specializing in working with Autism Spectrum Disorder. The Company plans to provide Eleotin products to the school. The Company is also pleased to announce the launch of new products: Eleotin Kalimera Hypno, Eleotin MCE, Eleotin Waikiki, and new generation of Eleotin Mb teas. Eleotin Kalimera Hypno is the Company’s first melatonin product, to be used to help with the body’s sleep-wake cycles. Eleotin MCE addresses sexual health, and Eleotin Waikiki is a combination of coral calcium and Vitamin D. The new Eleotin Mb teas are the first products of the Company’s anticipated line of health drink powders. The Company has also begun mass production of Eleotin Katharos, the anti-oxidant product that has been received in Asia as way to address heavy metals and smog in the environment. Yunji Kim, President and CEO, commented, “We are pleased with this new partnership with Beseto, but it is at an exploratory stage. We do not have any projections at this time of what profits or revenues may result. We also do not claim any effect our products may have, except for the claims allowed by the various governmental authorities.” About Eastwood Bio-Medical Canada, Inc.: The Company is a Vancouver based company whose Eleotin brand of products provide natural sourced solutions for metabolic syndromes, such as blood glucose control, obesity, and hypertension. Eleotin was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-Medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin products have been endorsed by thousands of doctors and medical associations around the globe, and authorized by Advertising Standards Canada (ASC) to be marketed as the ‘World’s #1 Doctor Recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada’. More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca. For further information, please contact: Eastwood Bio-Medical Canada Inc. Yunji Kim, President and Chief Executive Officer Telephone: (604) 247-2100 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forwardlooking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products or partnership will produce revenue increases. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
